🚀 VC round data is live in beta, check it out!
Oncocross Valuation Multiples
Discover revenue and EBITDA valuation multiples for Oncocross and similar public comparables like Annovis Bio, Türk İlaç, BGM Group, NetraMark and more.
Oncocross Overview
About Oncocross
Oncocross Co Ltd is innovating the drug development process through its AI approach for developing treatments for cancers, rare diseases, and intractable diseases, thereby contributing to a healthier world. Its Technology platforms include ONCOCROSS AI Platform, RAPTOR AI, ONCO-RAPTOR AI, and ONCOfind AI.
Founded
2015
HQ
Employees
N/A
Website
Financials (FY)
EV
$52M
Oncocross Financials
Oncocross reported last fiscal year revenue of $251K and negative EBITDA of ($5M).
In the same fiscal year, Oncocross generated $251K in gross profit, ($5M) in EBITDA losses, and had net loss of ($6M).
Oncocross P&L
In the most recent fiscal year, Oncocross reported revenue of $251K and EBITDA of ($5M).
Oncocross expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $251K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $251K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 100% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($5M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (2049%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (2384%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($6M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (2410%) | XXX | XXX | XXX |
| Net Debt | — | — | $2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Oncocross Stock Performance
Oncocross has current market cap of $65M, and enterprise value of $52M.
Market Cap Evolution
Oncocross' stock price is $5.39.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $52M | $65M | -2.9% | XXX | XXX | XXX | $-0.50 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOncocross Valuation Multiples
Oncocross trades at 209.4x EV/Revenue multiple, and (10.2x) EV/EBITDA.
Oncocross Financial Valuation Multiples
As of April 19, 2026, Oncocross has market cap of $65M and EV of $52M.
Equity research analysts estimate Oncocross' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oncocross has a P/E ratio of (10.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $65M | XXX | $65M | XXX | XXX | XXX |
| EV (current) | $52M | XXX | $52M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 209.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (10.2x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (8.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 209.4x | XXX | XXX | XXX |
| P/E | — | XXX | (10.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oncocross Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Oncocross Margins & Growth Rates
Oncocross' revenue in the last fiscal year declined by (65%).
Oncocross Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (65%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (2049%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 25% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 295% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 62% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 890% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 2484% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Oncocross Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Health Data & Analytics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Oncocross | XXX | XXX | XXX | XXX | XXX | XXX |
| Annovis Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Türk İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| BGM Group | XXX | XXX | XXX | XXX | XXX | XXX |
| NetraMark | XXX | XXX | XXX | XXX | XXX | XXX |
| TScan Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oncocross M&A Activity
Oncocross acquired XXX companies to date.
Last acquisition by Oncocross was on XXXXXXXX, XXXXX. Oncocross acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Oncocross
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOncocross Investment Activity
Oncocross invested in XXX companies to date.
Oncocross made its latest investment on XXXXXXXX, XXXXX. Oncocross invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Oncocross
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oncocross
| When was Oncocross founded? | Oncocross was founded in 2015. |
| Where is Oncocross headquartered? | Oncocross is headquartered in South Korea. |
| Is Oncocross publicly listed? | Yes, Oncocross is a public company listed on Korea Exchange. |
| What is the stock symbol of Oncocross? | Oncocross trades under 382150 ticker. |
| When did Oncocross go public? | Oncocross went public in 2024. |
| Who are competitors of Oncocross? | Oncocross main competitors are Annovis Bio, Türk İlaç, BGM Group, NetraMark. |
| What is the current market cap of Oncocross? | Oncocross' current market cap is $65M. |
| What is the current revenue of Oncocross? | Oncocross' last fiscal year revenue is $251K. |
| What is the current EV/Revenue multiple of Oncocross? | Current revenue multiple of Oncocross is 209.4x. |
| Is Oncocross profitable? | No, Oncocross is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.